OliX PharmaceuticalsInc (226950) — Cash Flow-to-Debt Ratio
OliX PharmaceuticalsInc (226950) has a Cash Flow-to-Debt Ratio of -0.27x as of December 2025, meaning its operating cash flow of ₩-12.16 Billion could theoretically repay 0% of its total liabilities (₩45.29 Billion) in one year. Explore long-term investment intensity of OliX PharmaceuticalsInc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
OliX PharmaceuticalsInc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for OliX PharmaceuticalsInc across 10 annual periods. Also explore 226950 total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for OliX PharmaceuticalsInc (2016–2025)
Year-by-year debt coverage analysis for OliX PharmaceuticalsInc. For market capitalisation and broader financial context, see OliX PharmaceuticalsInc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | ₩-15.90 Billion | ₩45.29 Billion | ▲ +33.1% |
| 2024 | -0.53x | ₩-28.04 Billion | ₩53.40 Billion | ▼ -30.2% |
| 2023 | -0.40x | ₩-21.17 Billion | ₩52.49 Billion | ▲ +12.3% |
| 2022 | -0.46x | ₩-30.68 Billion | ₩66.74 Billion | ▼ -64.4% |
| 2021 | -0.28x | ₩-19.05 Billion | ₩68.15 Billion | ▼ -147.6% |
| 2020 | -0.11x | ₩-3.76 Billion | ₩33.29 Billion | ▲ +96.4% |
| 2019 | -3.15x | ₩-10.73 Billion | ₩3.41 Billion | ▲ +73.7% |
| 2018 | -11.96x | ₩-8.36 Billion | ₩698.94 Million | ▼ -640.5% |
| 2017 | -1.62x | ₩-4.79 Billion | ₩2.96 Billion | ▼ -21.4% |
| 2016 | -1.33x | ₩-3.45 Billion | ₩2.59 Billion | — |